Results 61 to 70 of about 4,681 (114)

Pancreatic, nutritional and clinical outcomes in children 0-5 years with cystic fibrosis during the first 2 years of CFTR modulator therapy (PaNC): a multicentre prospective observational study protocol. [PDF]

BMJ Open
Miles C, Katz T, Grunert J, Ford K, Hall C, Hawthorn C, See DW, McMahon M, Vass H, Watkins S, Zanardo G, Brookes I, Handley S, Woodward T, Wademan J, Cameron B, King S, Nixon GM, Davidson Z.   +18 more
europepmc   +1 more source

Kidney effects of triple CFTR modulator therapy in people with cystic fibrosis. [PDF]

Clin Kidney J
Gabai P, Novel-Catin E, Reynaud Q, Nove-Josserand R, Pelletier S, Fouque D, Koppe L, Durieu I.   +7 more
europepmc   +1 more source

The effect of triple CFTR modulator therapy and azithromycin on ion channels and inflammation in cystic fibrosis. [PDF]

ERJ Open Res
Bani Melhim S, Douglas LEJ, Reihill JA, Downey DG, Martin SL.   +4 more
europepmc   +1 more source

Type 2 inflammation in cystic fibrosis is a predictor of mortality and targeted with CFTR modulator therapy. [PDF]

Allergy
Cook DP, Wu AY, Thomas CM, Hamilton RG, Peebles RS, Kerchberger VE.   +5 more
europepmc   +1 more source

Changing profile of bacterial infection and microbiome in cystic fibrosis: when to use antibiotics in the era of CFTR-modulator therapy. [PDF]

Eur Respir Rev
Milczewska J, Syunyaeva Z, Żabińska-Jaroń A, Sands D, Thee S.   +4 more
europepmc   +1 more source

Heightened mitochondrial respiration in CF cells is normalised by triple CFTR modulator therapy through mechanisms involving calcium. [PDF]

Heliyon
Jarosz-Griffiths HH, Caley LR, Lara-Reyna S, Savic S, Clifton IJ, McDermott MF, Peckham DG.   +6 more
europepmc   +1 more source

Heterogeneity of CFTR modulator-induced sweat chloride concentrations in people with cystic fibrosis. [PDF]

J Cyst Fibros
Zemanick ET, Emerman I, McCreary M, Mayer-Hamblett N, Warden MN, Odem-Davis K, VanDevanter DR, Ren CL, Young J, Konstan MW, CHEC-SC Study Group.   +10 more
europepmc   +1 more source

Organic Synthesis and Current Understanding of the Mechanisms of CFTR Modulator Drugs Ivacaftor, Tezacaftor, and Elexacaftor. [PDF]

Molecules
Ferreira FC, Buarque CD, Lopes-Pacheco M.   +2 more
europepmc   +1 more source

Considerations for the use of inhaled antibiotics for Pseudomonas aeruginosa in people with cystic fibrosis receiving CFTR modulator therapy. [PDF]

BMJ Open Respir Res
Burgel PR, Ballmann M, Drevinek P, Heijerman H, Jung A, Mainz JG, Peckham D, Plant BJ, Schwarz C, Taccetti G, Smyth A.   +10 more
europepmc   +1 more source

Laboratory Tools to Predict CFTR Modulator Therapy Effectiveness and to Monitor Disease Severity in Cystic Fibrosis. [PDF]

J Pers Med
Bacalhau M, Camargo M, Lopes-Pacheco M.
europepmc   +1 more source